三唑类药物预暴露对米根霉易感性和毒力的影响。
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
作者信息
Bellanger Anne-Pauline, Albert Nathaniel D, Lewis Russell E, Walsh Thomas J, Kontoyiannis Dimitrios P
机构信息
Department of Infectious Diseases, MD Anderson Cancer Center, Houston, Texas, USA Chrono-Environment UMR 6249 Research Team, Franche-Comté University and Parasitology-Mycology Department, Central University Hospital (CHU), Besançon, France.
Department of Infectious Diseases, MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7830-2. doi: 10.1128/AAC.01583-15. Epub 2015 Sep 21.
Abstract
Triazole prophylaxis has become the norm in patients with hematological malignancies. Breakthrough infections caused by Mucorales during triazole prophylaxis remain a challenging problem. We found that preexposure of Rhizopus oryzae to antifungal triazoles (fluconazole, voriconazole, posaconazole, and itraconazole) did not modify the in vitro susceptibility of Rhizopus oryzae to posaconazole. In contrast, preexposure of Rhizopus to triazoles was associated with the enhanced in vitro susceptibility of R. oryzae to amphotericin B. Preexposure to posaconazole did not alter the virulence of R. oryzae in the fly model of mucormycosis.
摘要
三唑类预防用药已成为血液系统恶性肿瘤患者的常规治疗方法。在三唑类预防用药期间，由毛霉目真菌引起的突破性感染仍然是一个具有挑战性的问题。我们发现，米根霉预先暴露于抗真菌三唑类药物（氟康唑、伏立康唑、泊沙康唑和伊曲康唑）并不会改变米根霉对泊沙康唑的体外敏感性。相比之下，米根霉预先暴露于三唑类药物与米根霉对两性霉素B的体外敏感性增强有关。预先暴露于泊沙康唑并不会改变米根霉在毛霉病果蝇模型中的毒力。
相似文献
1
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Antimicrob Agents Chemother. 2015 Dec;59(12):7830-2. doi: 10.1128/AAC.01583-15. Epub 2015 Sep 21.
2
Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Med Mycol. 2008 Sep;46(6):567-73. doi: 10.1080/13693780801975576.
3
Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
Virulence. 2011 Jul-Aug;2(4):348-55. doi: 10.4161/viru.2.4.17074. Epub 2011 Jul 1.
4
Preexposure to Isavuconazole Increases the Virulence of but Not in a Infection Model.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01896-18. Print 2019 Feb.
5
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.
Antimicrob Agents Chemother. 2006 Nov;50(11):3917-9. doi: 10.1128/AAC.00747-06. Epub 2006 Sep 11.
6
Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
J Infect Dis. 2013 Mar 1;207(5):834-41. doi: 10.1093/infdis/jis767. Epub 2012 Dec 13.
7
Efficacy of Posaconazole against Rhizopus oryzae Infection in Silkworm.
Med Mycol J. 2021;62(3):53-57. doi: 10.3314/mmj.21-00004.
8
In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
J Mycol Med. 2016 Mar;26(1):17-21. doi: 10.1016/j.mycmed.2015.12.002. Epub 2016 Feb 4.
9
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
J Infect Dis. 2009 May 1;199(9):1399-406. doi: 10.1086/597615.
10
Hyperthermia sensitizes Rhizopus oryzae to posaconazole and itraconazole action through apoptosis.
Antimicrob Agents Chemother. 2013 Sep;57(9):4360-8. doi: 10.1128/AAC.00571-13. Epub 2013 Jul 1.
引用本文的文献
1
Commemorating the Landmark Advances in Our Understanding of Mucormycosis by Dimitrios P. Kontoyiannis.
J Fungi (Basel). 2025 Jun 6;11(6):435. doi: 10.3390/jof11060435.
2
The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research.
J Fungi (Basel). 2024 May 27;10(6):382. doi: 10.3390/jof10060382.
3
Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.
Eur J Med Chem. 2023 Jan 15;246:115010. doi: 10.1016/j.ejmech.2022.115010. Epub 2022 Dec 10.
4
Functional Genomic and Biochemical Analysis Reveals Pleiotropic Effect of Congo Red on Aspergillus fumigatus.
mBio. 2021 May 18;12(3):e00863-21. doi: 10.1128/mBio.00863-21.
5
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.
Mycoses. 2019 Sep;62(9):716-729. doi: 10.1111/myc.12960. Epub 2019 Jul 19.
6
Animal Models to Study Mucormycosis.
J Fungi (Basel). 2019 Mar 27;5(2):27. doi: 10.3390/jof5020027.
7
In Vitro and In Vivo Evaluation of Voriconazole-Containing Antifungal Combinations against Mucorales Using a Model of Mucormycosis.
J Fungi (Basel). 2019 Jan 8;5(1):5. doi: 10.3390/jof5010005.
8
Preexposure to Isavuconazole Increases the Virulence of but Not in a Infection Model.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01896-18. Print 2019 Feb.
9
Therapy of Mucormycosis.
J Fungi (Basel). 2018 Jul 31;4(3):90. doi: 10.3390/jof4030090.
10
Gene Mutations and Upregulation Confer Pan-Azole Resistance in Candida tropicalis Causing Disseminated Candidiasis in an Acute Lymphoblastic Leukemia Patient on Posaconazole Prophylaxis.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.02496-16. Print 2017 Jul.
本文引用的文献
1
Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis.
Infect Chemother. 2015 Mar;47(1):49-54. doi: 10.3947/ic.2015.47.1.49. Epub 2015 Mar 30.
2
Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
J Antimicrob Chemother. 2014 Nov;69(11):3142-7. doi: 10.1093/jac/dku227. Epub 2014 Jun 19.
3
Epidemiology and treatment of mucormycosis.
Future Microbiol. 2013 Sep;8(9):1163-75. doi: 10.2217/fmb.13.78.
4
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
Clin Infect Dis. 2012 Dec;55(11):1515-21. doi: 10.1093/cid/cis773. Epub 2012 Sep 5.
5
Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
Virulence. 2011 Jul-Aug;2(4):348-55. doi: 10.4161/viru.2.4.17074. Epub 2011 Jul 1.
6
Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Clin Microbiol Infect. 2009 Oct;15 Suppl 5:93-7. doi: 10.1111/j.1469-0691.2009.02988.x.
7
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
J Infect Dis. 2009 May 1;199(9):1399-406. doi: 10.1086/597615.
8
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9367-72. doi: 10.1073/pnas.0709578105. Epub 2008 Jun 26.
9
Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
J Antimicrob Chemother. 2008 Sep;62(3):539-42. doi: 10.1093/jac/dkn224. Epub 2008 Jun 10.
10
Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.
J Infect Dis. 2006 Oct 1;194(7):1008-18. doi: 10.1086/506617. Epub 2006 Aug 28.
Zotero 插件